UCare’s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to UCare formularies (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for the Medicare formularies are tentative until UCare receives final CMS approval.

Key:

Medicare: UCare Medicare, UCare Group Medicare, EssentiaCare, Minnesota Senior Health Options (MSHO) & Connect + Medicare

Medical Assistance: PMAP, MnCare, MSC+ & Connect

Exchange: UCare Individual and Family Plans

F: Formulary

NF: Non-formulary

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

|  |
| --- |
| New Drug Review |

|  |  |  |  |
| --- | --- | --- | --- |
| **Drug**  | **Indication** | **Formulary Coverage** | **Effective Date** |
| **Alyfrek** (vanzacaftor, tezacaftor, and deutivacaftor) | Treatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. | Medicare: FormularyMedical Assistance: FormularyExchange: Formulary  | 8/1/2025 |
| **Itovebi** (inavolisib) **Protected Class Drug** | PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer (mBC) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) for the treatment of adults with endocrine-resistant, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. | Medicare: FormularyMedical Assistance: FormularyExchange: Formulary | 8/1/2025 |
| **Sofdra** (sofprionium) | Hyperhidrosis of axilla | Medicare: Non-Formulary Medical Assistance: Non-FormularyExchange: Non-Formulary | N/A |
| **Cobenfy** (xanomeline/trospium) | Treatment of schizophrenia in adults | Medicare: FormularyMedical Assistance: Non-PreferredExchange: Non-Formulary | 8/1/2025 |
| **Tryvio** (aprocitentan) | Treatment of hypertension (HTN) in combination with other antihypertensive drugs, to lower blood pressure (BP) in adults who are not adequately controlled on other drugs. | Medicare: Non-Formulary Medical Assistance: Non-FormularyExchange: Non-Formulary | N/A |
| **Agneursa** (levacetylleucine) | Aqneursa is indicated for the treatment of neurological manifestations of NiemannPick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. | Medicare: Non-Formulary Medical Assistance: Non-FormularyExchange: Non-Formulary | N/A |
| **Miplyffa** (arimoclomol) | Miplyffa is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. | Medicare: Non-Formulary Medical Assistance: Non-FormularyExchange: Non-Formulary | N/A |

|  |
| --- |
| New Indications Review |

|  |  |  |
| --- | --- | --- |
| **Drug** | **Current formulary status** | **Recommendation** |
| **Odefsey** (emtricitambine-rilpivirine-tenofovir alafenamide) 200-25-25 mg tablets for HIV in adults and pediatric patients weighing ≥ 25 kg indication expansion | F: all lines of business | No change |
| **Sublocade** (buprenorphine ER) 100 mg/0.5 mL & 300 mg/1.5 mL SQ syringes for moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of transmucosal buprenorphine or are already being treated with buprenorphine indication expansion | NF: Medicare, PPO, IFPNP: Medicaid | No change |
| **Adcetris** (brentuximab vedotin) IV vial in combination with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma | NF: All lines of business | No change |
| **Tevimbra** (tislelizumab) in combination with platinum-containing chemotherapy for the first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (≥ 1) | NF: All lines of business | No change |
| **Furoscix** (furosemide) 80 mg/10 mL SQ On-body infusor for edema in adults with chronic kidney disease, including nephrotic syndrome | NF: All lines of business | No change |
| **Odactra** (house dust mite allergen extract) tablets for house dust mite allergies for patients 5 to 65 years age expansion | NF: All lines of business | No change |
| **Synjardy** [XR] (empagliflozin-metformin [ER]) tablets to reduce the risk of sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with type 2 diabetes & CKD at risk of progression | F: Medicare, PPO, IFPPDL: Medicaid | No change |
| **Baqsimi** (glucagon) 3 mg nasal powder for severe hypoglycemia in patients ≥ 1 year with diabetes age expansion | NF: Medicare, PPOF: IFPPDL: Medicaid | No change |
| **Rivfloza** (nedosiran) 160 mg/mL SQ injection to lower urinary oxalate levels in patients ≥ 2 years with primary hyperoxaluria type 1 age expansion | NF: All lines of business | No change |
| **Susvimo** (ranibizumab) 100 mg/mL intravitreal ocular implant for diabetic macular edema in patients who previously responded to at least 2 intravitreal injections of a VEGF inhibitor | NF: All lines of business | No change |
| **Soliris** (eculizumab) 10 mg/mL IV vial for generalized myasthenia gravis in patients ≥ 6 years age expansion | NF: All lines of business | No change |
| **Keytruda** (pembrolizumab) 25 mg/mL IV solution traditional approval for HER2+ gastric/GEJ cancer | NF: All lines of business | No change |
| **Imfinzi** (durvalumab) 50 mg/mL IV solution in combination with gemcitabine and cisplatin followed by durvalumab monotherapy for muscle invasive bladder cancer | NF: All lines of business | No change |
| **Fabhalta** (iptacopan) 200 mg capsules for complement 3 glomerulopathy to reduce proteinuria | NF: All lines of business | No change |
| **Cabometyx** (cabozantinib) 20, 40, & 60 mg tablets for neuroendocrine tumors | F: All lines of business | No change |
| **Rinvoq** (upadacitinib) 15 mg ER tablets for giant cell arteritis | F: Medicare, PPO, IFPNP: Medicaid | No change |
| **Isturisa** (osilodrostat) 1 & 5 mg tablets for endogenous hypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative | NF: Medicare, PPO, IFPNP: Medicaid | No change |
| **Eliquis** (apixaban) 2.5 & 5 mg tablets, 0.5 mg tablets for oral suspension, & 0.15 mg sprinkle capsules for oral suspension for VTE in pediatric patients age expansion | F: All lines of business | No change |
| **Sivextro** (tedizolid) 200 mg tablets for acute bacterial skin and skin structure infections in pediatric patients age expansion | NF: All lines of business | No change |
| **Amvuttra** (vutrisiran) 25 mg/0.5 mL prefilled syringe for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis | NF: All lines of business | No change |
| **Uplizna** (inebilizumab) 10 mg/mL IV vials for Immunoglobulin G4-related disease | NF: All lines of business | No change |
| **Opdivo** (nivolumab) in combination with Yervoy (ipilimumab) for (1) first-line treatment of hepatocellular carcinoma and (2) MSI-H or dMMR colorectal cancer full approval (also applies to nivolumab as single agent) | NF: All lines of business | No change |

|  |
| --- |
| New Generics Review  |

|  |  |  |
| --- | --- | --- |
| **Drug** | **Rationale/Alternative** | **Recommendation** |
| **Galzin** (zinc acetate) 25 mg & 50 mg capsules for Wilson’s disease authorized generic | An authorized generic launched for zinc acetate capsules. | NF: all lines of business |
| **Auranofin** 3 mg capsule for rheumatoid arthritis authorized generic | An authorized generic launched for auranofin which is indicated for active classical or definite rheumatoid arthritis in patients who have failed or are intolerant to ≥ 1 nonsteroidal anti-inflammatory drug. | NF: all lines of business |
| **Pyzchiva** (ustekinumab-ttwe) 45 mg/0.5 mL & 90 mg/mL prefilled syringes for various inflammatory conditions | An additional ustekinumab biosimilar has launched under brand name Pyzchiva in 45 mg and 90 mg formulations. | NF: all lines of business |
| **Pyzchiva** (ustekinumab-ttwe) 130 mg/26 mL IV vial for IV induction for IBD indications | Additional IV formulation launch of Pyschiva | NF: all lines of business |
| **Ivra** (melphalan) 90 mg/mL IV vial for multiple myeloma | The 90 mg/mL melphalan IV solution is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. | NF: all lines of business |
| Namzaric (**memantine-donepezil**) 21-10 mg ER capsule for Alzheimer’s disease | A generic for the 21/10 mg strength of Namzaric has launched, joining the 28/10 mg and 14/10 mg strengths | NF: all lines of business |
| **Otulfi** (ustekinumab-aauz) 45 mg/0.5 mL & 90 mg/mL prefilled syringes for various conditions | New Ustekinumab biosimilar for Stelara has launched | NF: Medicare, PPO, IFPF: Medicaid |
| Purixan (**mercaptopurine**) 2000 mg/100 mL oral suspension for acute lymphoblastic leukemia | A generic version of Purixan has launched at a marginal price decrease from the branded agent. | NF: Medicaid, IFPF: Medicare, PPO |
| Xarelto (**rivaroxaban**) 2.5 mg tablet for anticoagulation | Xarelto (rivaroxaban) 2.5 mg strength recently became generically available, with the higher strength tablets still only available as the brand. | F: all lines of business |
| **Simlandi** (adalimumab-ryvk) 80 mg/0.8 mL auto-injector for various inflammatory conditions | New 80mg autoinjector launched | F: Medicare, PPO, IFPNP: Medicaid |
| **Adalimumab-adaz** 10 mg/0.1 mL prefilled syringe for various inflammatory conditions | New adalimumab-adaz strength launched | NF: Medicare, PPO, IFPNP: Medicaid |
| Auryxia (**ferric citrate**) 1 gm (210 mg ferric iron) for hyperphosphatemia and iron deficient anemia in CKD | Ferric citrate authorized generic launched at a ~9% discount from the branded product. | NF: all lines of business |
| **Sandostatin LAR Depot** (octreotide) 10 mg IMkit for acromegaly & severe diarrhea with certain tumors | New generic launch of 10mg alongside 20mg and 30mg | NF: all lines of business |
| Brilinta (**ticagrelor**) 60 mg & 90 mg tablets antiplatelet therapy | A generic has launched for both the 60 mg and 90 mg strengths of ticagrelor (Brilinta equiv) tablets. | F: all lines of business |
| Anoro Ellipta (**umeclidinium-vilanterol**) 62.5-25 mcg/act inhaler for COPD | A new AG of umeclidinium-vilanterol recently launched. Anoro Ellipta is rebated and is lower net cost than the AG, which only has a 5% AWP reduction from the original branded product. | NF: Medicare, PPO, IFPF: Medicaid |
| **Adalimumab-aaty** 80 mg/0.8 mL starter kit [3 auto-injectors] for various inflammatory conditions | An 80 mg, 3 dose starter kit for adalimumab-aaty has launched to support new patients using the product for Crohn’s, ulcerative colitis, or hidradenitis suppurativa. | F: Medicare, PPO, IFPNP: Medicaid |
| J&J unbranded Stelara (**ustekinumab**) products | The manufacturer of Stelara, Johnson & Johnson, has released an unbranded version at a 75% list price discount for the prefilled syringes, 25% discount for the single use SC vial formulation, and 15% discount for the IV vial formulation. | NF: all lines of business |

|  |
| --- |
| New or Expanded Formulations  |

|  |  |  |
| --- | --- | --- |
| **Drug** | **Rationale/Alternative** | **Recommendation** |
| **Ergomar** (ergotamine) 2 mg sublingual tablet for migraine | An additional ergotamine sublingual tablet NDC launched. This product was originally FDA approved in the 1980s and is not commonly used, with many alternative preferred treatment options for migraine available. | NF: Medicare, PPO, MedicaidF: IFP |
| **Evrysdi** (risdiplam) 5 mg tablet for spinal muscular atrophy | Risdiplam for spinal muscular atrophy, previously available only as an oral solution, is now available as a tablet, offering an alternative dosage form for patients able to take tablets. | NF: Medicare, PPO, IFPF: Medicaid |
| **Palforzia** (peanut powder) 0.5 mg/1 mg/1.5 mg/3 mg starter pack and 1 mg sprinkle capsules for peanut allergy desensitization | New strengths and packs of peanut powder recently launched to accommodate the dosing regimen for the age expansion down to 1 year of age | NF: all lines of business |
| **Rybelsus** (semaglutide) 1.5 mg, 4 mg, & 9 mg tablets for type 2 diabetes | Three new strengths of semaglutide launched (previous strengths 3 mg, 7 mg, and 14 mg tablets). | F: Medicare, PPO, IFPNP: Medicaid |
| **Omvoh** (mirikizumab) 300 mg (100 mg/mL + 200 mg/2 mL) autoinjector and prefilled syringe for Crohn's disease | A new strength and package size presentation of mirikizumab has launched to accommodate the higher dosing required for the recent Crohn’s disease indication. | F: Medicare, PPO, IFPNP: Medicaid |
| **Zepbound** (tirzepatide) 7.5 mg/0.5 mL & 10 mg/0.5 mL SQ vials for weight management | Higher strength vials of Zepbound have been released, adding 7.5 mg and 10 mg vials to the existing 2.5 and 5 mg vials. | F: Medicare, PPO, IFPNP: Medicaid  |
| **Xromi** (hydroxyurea) 100 mg/mL oral solution for sickle cell disease | A new liquid formulation of hydroxyurea has launched for patients unable to use solid dosage forms | NF: all lines of business |
| **Metaxalone** 640 mg tablet for musculoskeletal conditions | Metaxalone 640 mg is a unique strength, joining the generic 400 mg and 800 mg strength tablets. WAC = $41.75/tab | NF: all lines of business |
| **Onapgo** (apomorphine) 98 mg/20 mL SQ solution for Parkinson’s disease | Onapgo is given by subcutaneous infusion via Onapgo pump. Alternative therapies include injection and inhalation powder | NF: all lines of business |
| **Zunveyl** (benzgalantamine) 5 mg, 10 mg & 15 mg tablets for Alzheimer’s disease | Benzgalantamine was designed to reduce the gastrointestinal side effects associated with use of the generically available galantamine | NF: all lines of business |
| **Raldesy** (trazodone) 10 mg/mL oral solution for major depressive disorder in adults | Raldesy is a new oral solution formulation of trazodone, previously only available in tablet form, indicated for treatment of major depressive disorder in adults. | F: Medicare, PPONF: Medicaid, IFP |
| **Cortrophin** (corticotropin) 40 units/0.5 mL & 80 units/mL SQ prefilled syringes for various indications | Similar to a change for Acthar that occurred last year, Cortrophin is now available as a single-dose prefilled syringe providing 40 or 80 units per injection. | NF: all lines of business |
| **Inzirqo** (hydrochlorothiazide) 10 mg/mL oral suspension for hypertension & edema associated with heart failure, renal, or hepatic disease | Approved via the 505(b)(2) pathway, Inzirqo is an oral suspension formulation of hydrochlorothiazide | NF: all lines of business |
| **Xpovio** (selinexor) 10 mg tablet therapy pack (40 mg once weekly) for multiple myeloma & diffuse large B-cell lymphoma | A new 28-day dosage pack for selinexor (4 x 10 mg tablets), to accommodate a 40 mg dose taken once weekly, has launched. | F: all lines of business |
| **Sevenfact** (recombinant coagulation factor VIIa-jncw) 2 mg IV vial for hemophilia A or B with inhibitors | A new 2 mg strength vial of recombinant coagulation factor VIIa recently launched, previously available as 1 mg and 5 mg vials. | F: Medicare, PPONF: IFPPDL: Medicaid |
| **Ivermectin** 6 mg tablet for parasitic infections | A new 6 mg ivermectin tablet was relaunched as it was discontinued in 2009. The relaunched 6 mg tablet has a unit WAC of $10.35. | NF: all lines of business |
| **Combogesic** (ibuprofen-acetaminophen) 97.5-325 mg tablet for pain | A new FDA-approved, prescription only, 97.5 mg/325 mg strength of ibuprofen with acetaminophen recently launched. | NF: all lines of business |
| **Revuforj** (revumenib) 25 mg tablet for relapsed or refractory leukemia with a lysine methyltransferase 2A gene translocation | New 25mg strength launched alongside 110mg and 160mg | F: Medicare, PPONF: IFP, Medicaid |
| **Tremfya** (guselkumab) 20 mg/2 mL autoinjector induction pack for moderately to severely active Crohn’s disease | CD pack launched with the new FDA approval for moderate to severe CD | NF: Medicare, PPOF: IFPNP: Medicaid |
| **Ctexli** (chenodiol) 250 mg tablets for cerebrotendinous xanthomatosis & Chenodal (chenodiol) 250 mg tablets for gallstones | A new formulation of chenodiol (also known chemically as chenodeoxycholic acid) has launched in Ctexli. | NF: all lines of business |
| **Tezruly** (terazosin) 1 mg/mL oral solution for benign prostatic hyperplasia and hypertension | Tezruly, an oral terazosin solution, was approved through the 505(b)(2) pathway. | NF: all lines of business |
| **Neffy** (epinephrine) 1 mg/0.1 mL nasal spray for allergic reactions in patients 15 kg to < 30 kg | New lower dose for patients 15kg to <30kg | NF: Medicare, PPOF: IFP, Medicaid |
| **Sunlenca** (lenacapavir) 300 mg tablets for HIV [4 tablet bottle] | New packaging of the same 300mg tablets (previously only available in blister packs) | F: all lines of business |
| **Paxlovid** (nirmatrelvir/ritonavir) 6 x 150 mg/5 x 100 mg tablet pack for COVID-19 | A new packaging for Paxlovid recently launched to accommodate the dosing in those with severe renal impairment (eGFR < 30 mL/min) including those requiring hemodialysis. | F: all lines of business |
| **Bisoprolol** 2.5 mg tablets for hypertension | A single-source branded 2.5 mg strength of bisoprolol launched. >14x the cost of the 5mg tablet | NF: all lines of business |
| **Dolobid** (diflunisal) 375 mg tablet & 250 mg tablet (previously available) for pain | An additional 375 mg strength of Dolobid (diflunisal) launched. >60x the cost of the generically available 500mg tablet | NF: all lines of business |
| **Symbravo** (meloxicam-rizatriptan) 20-10 mg tablet for migraine | A new combination of meloxicam and rizatriptan has launched, with a price of $128 per tablet. | NF: all lines of business |
| **Feriva** 21/7 Rx multivitamin tablet with iron & **Prenate Max** Rx prenatal vitamin with iron | Feriva and Prenate Max are prescription-only multivitamins, one of which is a prenatal vitamin. | NF: all lines of business |
| **Hemiclor** (chlorthalidone) 12.5 mg tablets for hypertension | Hemiclor is a branded 12.5 mg oral chlorthalidone tablet approved through the 505(b)(2) pathway. | NF: all lines of business |

|  |
| --- |
| Additional Items Reviewed |

|  |  |
| --- | --- |
| **Item** | **Drugs with New Policies** |
| New Medical Drug Policies (effective 8/1/2025) | * Emrelis
* Envelto
* Imaavy
 |